Silence Therapeutics PLC (SLNCF) SEC Filings — 2025

Filings

• Silence Therapeutics Files 8-K/A Amendment on Officer/Director Changes — 8-K/A · Dec 22, 2025
• Silence Therapeutics Announces CMO Departure, Appoints Interim — 8-K · Dec 15, 2025
• Silence Therapeutics' Losses Widen Amid R&D Surge, Revenue Plunge — 10-Q · Nov 6, 2025
• Silence Therapeutics Files 8-K — 8-K · Oct 23, 2025
• Silence Therapeutics Announces Board and Officer Changes — 8-K · Aug 14, 2025
• Silence Therapeutics Files 8-K on Financials — 8-K · Aug 7, 2025
• Silence Therapeutics' Q2 Loss Widens Amid Declining Collaboration Revenue — 10-Q · Aug 7, 2025
• Silence Therapeutics Reports on Shareholder Vote Matters — 8-K · Jun 27, 2025
• Silence Therapeutics DEF 14A: Executive Compensation Details — DEF 14A · May 16, 2025
• Silence Therapeutics plc Files 8-K Report — 8-K · May 8, 2025
• Silence Therapeutics Q1 2025 Update — 10-Q · May 8, 2025
• Silence Therapeutics Announces CMO Departure, Interim Appointment — 8-K · May 6, 2025
• Silence Therapeutics Files 2024 Annual Report Amendment — 10-K/A · Apr 30, 2025
• Silence Therapeutics Files 8-K on Financials — 8-K · Feb 27, 2025
• Silence Therapeutics Files 2024 10-K — 10-K · Feb 27, 2025
• Silence Therapeutics Files 8-K — 8-K · Jan 2, 2025